Breaking News Instant updates and real-time market news.

ICPT

Intercept

$70.79

0.68 (0.97%)

07:04
04/13/18
04/13
07:04
04/13/18
07:04

Intercept announces data from liver biopsy substudy of POISE Phase 3 trial

Intercept Pharmaceuticals announced clinical data from a liver biopsy-based substudy from the POISE Phase 3 trial suggesting that long-term OCA treatment in patients with PBC was associated with reversal or stabilization of fibrosis and cirrhosis. The data are being presented at the International Liver Congress 2018, the 53rd Annual Meeting of the European Association for the Study of the Liver, in Paris, France, from April 11-15, 2018. OCA is not currently indicated for the reversal of fibrosis or cirrhosis in patients with PBC. Prior longitudinal biopsy studies have shown that patients who are not treated with, or have an inadequate response to, ursodeoxycholic acid, the current standard of care, are at significantly higher risk of fibrosis progression, liver failure, transplant and death. Liver biopsy is not the standard of care in PBC and difficult to obtain in clinical trials. In this voluntary substudy of the POISE Phase 3 trial, paired biopsies adequate for analysis were obtained for 13 patients, all of whom had liver fibrosis or cirrhosis at baseline. After three years of treatment with OCA, the majority of patients improved or maintained histological fibrosis stage, while two patients experienced one stage progression. Of the four patients with cirrhosis at baseline, all showed reversal by at least one stage, and three improved to fibrosis without cirrhosis. Pruritus is the most common symptom in patients with PBC and was also the most common adverse event in the POISE Phase 3 substudy. Nine patients experienced pruritus in the substudy, an incidence consistent with the rate observed in the broader study population. A total of five serious adverse events in five patients were reported. All serious adverse events were considered unlikely to be related, or not related, to OCA. A separate poster, "Durable Response in the Markers of Cholestasis through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis," presented at the International Liver Congress provided additional results from the open-label extension of the POISE trial. Sustained improvements in ALP were observed through three years of OCA therapy, with similar improvements seen for GGT, ALT and AST. Mean total bilirubin remained below baseline throughout the three-year open-label period. The most common adverse event observed with OCA therapy was pruritus, resulting in the discontinuation of seven patients during the open-label extension treatment phase. An additional poster, "Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of POISE, 201, and 202," assessed changes in total bilirubin observed in the POISE Phase 3 trial and two Phase 2 trials. The analysis, which included patients with total bilirubin greater than or equal to0.67 times the upper limit of normal at baseline, found that total bilirubin increased after 12 months of placebo treatment and decreased after 12 months of treatment with OCA. In the double-blind phase of POISE, 14% of placebo-treated and 78% of OCA-treated patients with abnormal total bilirubin at baseline attained normal levels after 12 months. Further, of 10 placebo-treated and 20 OCA-treated patients with normal total bilirubin at baseline, 60% of placebo-treated and 15% of OCA-treated patients worsened to abnormal total bilirubin after 12 months. Per EASL clinical guidelines, increasing bilirubin levels - even within the normal range - indicate progressive disease and are strongly associated with adverse clinical outcomes.

  • 13

    Apr

  • 20

    Apr

  • 08

    May

  • 21

    May

ICPT Intercept
$70.79

0.68 (0.97%)

03/28/18
LEER
03/28/18
NO CHANGE
Target $16
LEER
Outperform
More differentiating data at EASL can continue CymaBay momentum, says Leerink
Leerink analyst Joseph Schwartz expects a 6-month Phase 2 study update for CymaBay's (CBAY) seladelpar in primary biliary cholangitis to be reported at the International Liver Congress. The analyst notes CymaBay stock has enjoyed strong momentum since the preliminary 12-week data and he remains optimistic that seladelpar's profile will continue to look differentiated from Intercept's (ICPT) Ocaliva when it comes to safety/tolerability and efficacy in the second-line PBC treatment setting. The analyst reiterates an Outperform rating and $16 price target on CymaBay's shares.
02/13/18
WELS
02/13/18
NO CHANGE
Target $57
WELS
Market Perform
Intercept price target lowered to $57 from $62 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Intercept to $57 from $62 following his most recent review of the FDA AERS Safety Database for marketed bile acid analog OCALIVA, and significant increase in patient deaths in Q4. While Intercept has highlighted an independent safety review of post-marketing safety events cited in a September, 2017 FDA Drug Safety Communication, the analyst believes that significant increase in patient deaths in Q4 is concerning and the rate is above that predicted for the approved OCALIVA patient population by his estimate. Birchenough reiterates a Market Perform rating on the shares.
02/12/18
DBAB
02/12/18
NO CHANGE
Target $103
DBAB
Buy
Intercept study initiation a positive, says Deutsche Bank
Deutsche Bank analyst Navin Jacob views the initiation of the Reverse NASH trial is a positive for Intercept Pharmaceuticals, saying it "puts to rest any lingering bear arguments that OCA is not safe." The trial, if successful, presents potential upside to numbers, Jacob tells investors in a research note. He keeps a Buy rating on the shares with a $103 price target.
02/07/18
GSCO
02/07/18
DOWNGRADE
Target $45
GSCO
Sell
Intercept downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell and cut his price target for the shares to $45 from $74. The analyst sees a lack of catalyats to move the stock higher. Intercept closed yesterday up $2.08 to $60.82.

TODAY'S FREE FLY STORIES

GPOR

Gulfport Energy

$10.60

-0.39 (-3.55%)

16:48
10/18/18
10/18
16:48
10/18/18
16:48
Hot Stocks
Gulfport Energy reports Q3 net production 1,427.5 MMcfe per day, up 7% »

Gulfport Energy provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVLY

Codorus Valley Bancorp

$29.90

-0.2 (-0.66%)

16:47
10/18/18
10/18
16:47
10/18/18
16:47
Earnings
Codorus Valley Bancorp reports Q3 EPS 53c, consensus 37c »

Reports Q3 NII $16.4M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNW

Pinnacle West

$83.48

-0.235 (-0.28%)

16:43
10/18/18
10/18
16:43
10/18/18
16:43
Hot Stocks
Pinnacle West increases quarterly dividend 6.1% »

Pinnacle West Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 11

    Nov

  • 11

    Nov

CE

Celanese

$97.01

-2.76 (-2.77%)

16:37
10/18/18
10/18
16:37
10/18/18
16:37
Earnings
Celanese raises FY18 adjusted EPS view to $10.90-$11.10 from $10.50-$10.75 »

Consensus for FY18 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

JACK

Jack in the Box

$79.90

-2.29 (-2.79%)

16:36
10/18/18
10/18
16:36
10/18/18
16:36
Initiation
Jack in the Box initiated  »

Jack in the Box initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$86.24

0.9 (1.05%)

, ECYT

Endocyte

$23.40

7.85 (50.48%)

16:35
10/18/18
10/18
16:35
10/18/18
16:35
General news
Fly Intel: Wall Street's top stories for Thursday »

Stocks opened in negative…

NVS

Novartis

$86.24

0.9 (1.05%)

ECYT

Endocyte

$23.40

7.85 (50.48%)

TRV

Travelers

$125.08

-1.39 (-1.10%)

KO

Coca-Cola

$45.64

-0.22 (-0.48%)

AAPL

Apple

$215.98

-5.22 (-2.36%)

NFLX

Netflix

$346.71

-18.24 (-5.00%)

AMZN

Amazon.com

$1,771.45

-61.36 (-3.35%)

ACHC

Acadia

$38.57

2.8 (7.83%)

AA

Alcoa

$38.85

2.14 (5.83%)

APLS

Apellis

$13.80

-2.85 (-17.12%)

SNA

Snap-On

$151.46

-16.15 (-9.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 13

    Nov

  • 03

    Mar

CE

Celanese

$97.01

-2.76 (-2.77%)

16:35
10/18/18
10/18
16:35
10/18/18
16:35
Earnings
Celanese reports Q3 adjusted EPS $2.96, consensus $2.74 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

16:34
10/18/18
10/18
16:34
10/18/18
16:34
General news
Fed Balance Sheet Level data reported »

Week of 10/17 Fed Balance…

16:34
10/18/18
10/18
16:34
10/18/18
16:34
General news
Money Supply M2 Weekly Change data reported »

Week of 10/8 Money Supply…

ARGO

Argo Group

$60.43

-0.02 (-0.03%)

16:34
10/18/18
10/18
16:34
10/18/18
16:34
Hot Stocks
Argo Group sees Q3 pre-tax catastrophe losses of roughly $25M »

Argo Group announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 28

    Nov

GBCI

Glacier Bancorp

$41.19

-0.91 (-2.16%)

16:34
10/18/18
10/18
16:34
10/18/18
16:34
Earnings
Glacier Bancorp reports Q3 EPS 58c, consensus 60c »

Reports net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DNKN

Dunkin' Brands

$73.59

-0.88 (-1.18%)

16:34
10/18/18
10/18
16:34
10/18/18
16:34
Initiation
Dunkin' Brands initiated  »

Dunkin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ENFC

Entegra Financial

$23.80

-0.43 (-1.77%)

16:33
10/18/18
10/18
16:33
10/18/18
16:33
Earnings
Entegra Financial reports Q3 adjusted EPS 51c, consensus 56c »

Roger D. Plemens,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PLAY

Dave & Buster's

$59.90

-1.7 (-2.76%)

16:32
10/18/18
10/18
16:32
10/18/18
16:32
Initiation
Dave & Buster's initiated  »

Dave & Buster's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAL

Caleres

$33.29

-0.79 (-2.32%)

16:32
10/18/18
10/18
16:32
10/18/18
16:32
Hot Stocks
Caleres acquires Vionic for $360M »

Caleres announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTR

Nutrien

$54.54

-1.125 (-2.02%)

16:31
10/18/18
10/18
16:31
10/18/18
16:31
Upgrade
Nutrien rating change  »

Nutrien upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MU

Micron

$41.30

-1.06 (-2.50%)

, INTC

Intel

$44.98

-0.92 (-2.00%)

16:31
10/18/18
10/18
16:31
10/18/18
16:31
Hot Stocks
Micron intends to acquire remaining interest in IM Flash JV for about $1.5B »

Micron (MU) announced…

MU

Micron

$41.30

-1.06 (-2.50%)

INTC

Intel

$44.98

-0.92 (-2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

SFIX

Stitch Fix

$25.65

0.34 (1.34%)

, ZEN

Zendesk

$61.68

-1.29 (-2.05%)

16:31
10/18/18
10/18
16:31
10/18/18
16:31
Hot Stocks
Stitch Fix adds Mikkel Svane to Board of Directors »

Stitch Fix (SFIX)…

SFIX

Stitch Fix

$25.65

0.34 (1.34%)

ZEN

Zendesk

$61.68

-1.29 (-2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 13

    Nov

  • 06

    Dec

SYMC

Symantec

$19.97

-0.595 (-2.89%)

16:31
10/18/18
10/18
16:31
10/18/18
16:31
Initiation
Symantec initiated  »

Symantec initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

AAPL

Apple

$215.98

-5.22 (-2.36%)

16:30
10/18/18
10/18
16:30
10/18/18
16:30
Initiation
Apple initiated  »

Apple initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QLYS

Qualys

16:30
10/18/18
10/18
16:30
10/18/18
16:30
Initiation
Qualys initiated  »

Qualys initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

16:30
10/18/18
10/18
16:30
10/18/18
16:30
Initiation
Darden initiated  »

Darden initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOG

Extraction Oil & Gas

$10.49

-0.3 (-2.78%)

16:30
10/18/18
10/18
16:30
10/18/18
16:30
Hot Stocks
Extraction Oil & Gas sees Q3 average net sales volume of 75.7K BOE/d »

Sees FY18 production of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VMW

VMware

$145.51

-2.76 (-1.86%)

16:30
10/18/18
10/18
16:30
10/18/18
16:30
Initiation
VMware initiated  »

VMware initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Dec

ADBE

Adobe

$250.46

-8.44 (-3.26%)

16:30
10/18/18
10/18
16:30
10/18/18
16:30
Initiation
Adobe initiated  »

Adobe initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.